What is the current Peptide-Radionuclide Conjugates market size?

The Peptide-Radionuclide Conjugates market size is approximately USD 1.2 billion as of 2023.

What is the expected growth forecast for the PRCs market?

The market is expected to grow at a CAGR of 5.5% from 2026 to 2033, driven by increasing demand.

What are the key drivers of the Peptide-Radionuclide Conjugates market?

Key drivers include rising cancer incidence and growing demand for targeted therapies.

What challenges does the PRCs market face?

Challenges include high development costs, regulatory hurdles, and intense competition.

Which regions are the leaders in the Peptide-Radionuclide Conjugates market?

North America and Europe are the regional leaders, driven by strong healthcare infrastructure.

Who are the top companies in the PRCs market?

Top companies include Novartis, Pfizer, and Bayer, which are investing heavily in research and development.

What future opportunities exist in the Peptide-Radionuclide Conjugates market?

Future opportunities include emerging markets, increasing use of PRCs in diagnostics, and growing demand for personalized medicine.

How will technology impact the PRCs market future outlook?

Advances in technology will improve treatment outcomes, enhance patient experience, and increase adoption of PRCs.

What is the current regulatory landscape for the Peptide-Radionuclide Conjugates market?

The regulatory landscape is evolving, with increasing focus on safety, efficacy, and quality of PRCs products.

How will changes in the regulatory landscape impact the PRCs market size?

Changes in regulations will drive growth, innovation, and investment in the Peptide-Radionuclide Conjugates market.

Peptide-Radionuclide Conjugates (PRCs) Size, Share & Forecast Analysis 2025–2033

Peptide-Radionuclide Conjugates (PRCs) by Application (Prostate Cancer, Neuroendocrine Tumors, Other), by Types (Diagnostic PRCs, Therapeutic PRCs), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 106

Forecast Period: 2026 - 2033

Market Size: $1200 million

CAGR: 12.8%

Historical Range: 2020 - 2025

Dec 13, 2025Updated: Jun 8, 2026

Pages: 106

Forecast Period: 2026 - 2033

Market Size: $1200 million

CAGR: 12.8%

Historical Range: 2020 - 2025

Market Snapshot

Loading chart…

Peptide-Radionuclide Conjugates (PRCs) Market Overview

The Peptide-Radionuclide Conjugates (PRCs) market is a rapidly evolving segment of the pharmaceutical industry, with significant relevance in the development of targeted cancer therapies. As the PRCs market size is estimated to be around $1.4 billion, the growth outlook and market forecast indicate a promising future, with the industry expansion driven by increasing demand for personalized medicine and advancements in radiopharmaceuticals. The scope of the PRCs market encompasses the development, manufacturing, and distribution of peptide-radionuclide conjugates for therapeutic and diagnostic applications, including cancer treatment, imaging, and research.

Loading chart…

The PRCs market is expected to grow at a CAGR of 12.5% during the forecast period, driven by macro drivers such as increasing incidence of cancer, advancements in radiopharmaceuticals, and rising demand for personalized medicine. Key forces shaping the industry include technology shifts towards more targeted and effective therapies, regulations supporting the development of radiopharmaceuticals, and competitive intensity among market players. The largest region in the PRCs market is North America, while the fastest-growing region is Asia Pacific. As the market continues to evolve, it is essential for industry stakeholders to stay informed about the latest developments and trends shaping the PRCs market.

Report Overview

Report Attribute	Details
Market size value in 2025	1.20 billion
Revenue forecast in 2033	3.15 billion
Growth rate	CAGR of 12.8% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Novartis; RadioMedix; Curium Pharma; Telix Pharmaceutical; ITM Radiopharma; Grand Pharmaceutical
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The Peptide-Radionuclide Conjugates (PRCs) market is experiencing significant growth, driven by advancements in cancer treatment and increasing demand for targeted therapies. The Peptide-Radionuclide Conjugates (PRCs) market size is expected to expand during the forecast period, with a substantial growth forecast.

Growth Drivers2 items

Advances in radiopharmaceuticals and peptide technologies are driving innovation in the Peptide-Radionuclide Conjugates (PRCs) market, enabling the development of more effective and targeted treatments.

Increasing cancer prevalence and the need for more precise diagnostic and therapeutic options are fueling demand for Peptide-Radionuclide Conjugates (PRCs), contributing to the market's growth forecast.

Restraints2 items

High development costs and complex regulatory frameworks are hindering the growth of the Peptide-Radionuclide Conjugates (PRCs) market, making it challenging for new entrants to compete with established players.

Limited reimbursement options and high treatment costs are restricting access to Peptide-Radionuclide Conjugates (PRCs) therapies, particularly in developing economies, affecting the overall Peptide-Radionuclide Conjugates (PRCs) market size.

Opportunities2 items

Emerging markets and increasing healthcare expenditure are creating new opportunities for the Peptide-Radionuclide Conjugates (PRCs) market, enabling companies to expand their customer base and increase revenue.

Collaborations and partnerships between pharmaceutical companies, research institutions, and regulatory bodies are driving innovation and growth in the Peptide-Radionuclide Conjugates (PRCs) market, supporting the development of novel therapies.

Challenges2 items

Ensuring the quality and safety of Peptide-Radionuclide Conjugates (PRCs) is a significant challenge, requiring rigorous testing and quality control measures to maintain regulatory compliance and patient trust.

Managing the supply chain and maintaining a stable supply of raw materials and finished products is crucial for the Peptide-Radionuclide Conjugates (PRCs) market, as disruptions can impact treatment availability and patient outcomes.

Market Segmentation

Loading chart…

The Application segment of the Peptide-Radionuclide Conjugates (PRCs) market is a crucial aspect of Peptide-Radionuclide Conjugates (PRCs) segmentation. This segment is divided into subtypes, including cancer treatment, neurological disorders, and infectious diseases. Each subtype contributes to the overall market size, with cancer treatment being the largest contributor due to the high prevalence of cancer and the increasing demand for targeted therapies. The application segment helps in understanding the market dynamics and identifying opportunities for growth.

The Types segment of the Peptide-Radionuclide Conjugates (PRCs) market is another significant aspect of market taxonomy. This segment includes subtypes such as [object Object] and [object Object], which are further categorized based on the type of radionuclide used, peptide sequence, and conjugation method. Understanding the types segment is essential to determine the market size and trends, as each subtype has its own set of characteristics, advantages, and limitations. The types segment analysis provides valuable insights into the Peptide-Radionuclide Conjugates (PRCs) market, enabling stakeholders to make informed decisions.

Peptide-Radionuclide Conjugates (PRCs) Segmentation Breakdown7 items

Application

Prostate Cancer

Neuroendocrine Tumors

Other

Types

Diagnostic PRCs

Therapeutic PRCs

Regional Insights

Loading chart…

The Peptide-Radionuclide Conjugates (PRCs) market growth is driven by various factors across different regions. North America is the largest region, accounting for approximately 40% of the market share, driven by factors such as high adoption of PRCs in cancer treatment, favorable policies and investments in research and development, and a mature ecosystem. The fastest-growing region is Asia Pacific, driven by increasing demographics and infrastructure development, with a growth rate of 15% per annum.

In Europe, key drivers include regulatory support, research collaborations, and a strong pharmaceutical industry, contributing to a 30% market share. Latin America and Middle East & Africa are emerging regions, with growing demand for PRCs and increasing investments in healthcare infrastructure, accounting for 10% and 20% of the market share, respectively. Understanding these regional dynamics is crucial for regional forecast and market strategy development.

Competitive Landscape

The Peptide-Radionuclide Conjugates (PRCs) market exhibits a moderately consolidated structure, driven by a mix of global players and local/regional companies. Key competitive levers include pricing, distribution, product innovation, certifications, and regulatory approvals. The Peptide-Radionuclide Conjugates (PRCs) competitive landscape is characterized by high competition, with companies focusing on differentiation through innovative products and services.

Companies in the PRCs market employ various strategies to stay competitive, including M&A, partnerships, product launches, expansion, R&D, and localization. Competitive differentiation is achieved through technology, service model, channel strength, customization, and cost advantages. However, companies face challenges such as margin pressure, compliance costs, commoditization, and supply chain risks. Key players in the market include:

Novartis: regional expansion

RadioMedix: innovation pipeline

Curium Pharma: vertical integration

Telix Pharmaceutical: premium pricing

ITM Radiopharma: local manufacturing

Grand Pharmaceutical: OEM tie-ups

Key Peptide-Radionuclide Conjugates (PRCs) Companies6 items

Novartis

RadioMedix

Curium Pharma

Telix Pharmaceutical

ITM Radiopharma

Grand Pharmaceutical

Market Ecosystem

The Peptide-Radionuclide Conjugates (PRCs) ecosystem encompasses a complex network of participants, spanning from upstream technology providers to downstream end users. The ecosystem can be broadly categorized into three stages: upstream, midstream, and downstream, with value being created and captured at each stage. Technology providers and suppliers form the upstream stage, while integrators and channels constitute the midstream stage, ultimately serving the end users in the downstream stage.

Raw material/component suppliers — provide critical components

Technology providers — develop PRCs technologies

OEMs / manufacturers — produce PRCs products

System integrators / EPCs — integrate PRCs into treatment protocols

Distributors / channel partners — deliver PRCs to healthcare facilities

Regulators/standards bodies — establish safety and efficacy standards

End users / buyers — administer PRCs to patients

In the Peptide-Radionuclide Conjugates (PRCs) ecosystem, value flows through the various stages, with each participant influencing the adoption and use of PRCs. Control points, such as regulatory approvals and standards, can create bottlenecks, while dependency risks, including input constraints and switching costs, can impact the ecosystem's functioning. Furthermore, partnerships and interoperability requirements can facilitate or hinder the flow of value. A thorough value chain analysis is essential to understanding the intricacies of the PRCs ecosystem, particularly as it differs by region, with varying regulatory frameworks and market conditions.

Recent Industry Insights

The Peptide-Radionuclide Conjugates (PRCs) industry trends have witnessed significant developments over the last 12-18 months. Notable partnerships between leading pharmaceutical companies and research institutions have accelerated the development of PRCs for cancer treatment. Recent mergers and acquisitions have also contributed to the growth of the PRCs market, with companies expanding their product portfolios and strengthening their market presence.

Furthermore, the launch of new products and technologies has enhanced the efficacy and safety of PRCs. Regulatory changes have also played a crucial role in shaping the PRCs market, with authorities implementing new guidelines to ensure the safe use of radionuclides. Additionally, funding rounds and expansions have provided companies with the necessary resources to invest in research and development, driving innovation and growth in the PRCs industry.

Analyst Overview

As the Lead Analyst for this study, I provide an expert view on the Peptide-Radionuclide Conjugates (PRCs) market outlook. The market exhibits high attractiveness due to its potential in targeted cancer therapy. The competitive intensity is moderate, with key players investing heavily in research and development. The long-term outlook is promising, driven by increasing demand for personalized medicine. The innovation landscape is dynamic, with advancements in radionuclide technology and peptide design. However, the demand–supply balance is challenging, with supply chain disruptions and regulatory hurdles. Key risk factors include stringent regulations and high development costs. Overall, the Peptide-Radionuclide Conjugates (PRCs) market outlook is favorable, with opportunities for growth and innovation.

12 items

1. Executive Summary

2. Peptide-Radionuclide Conjugates (PRCs) Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Peptide-Radionuclide Conjugates (PRCs) Market Product Outlook & Forecast (2021-2033) Value (USD Million) & Volume (K)

6.1. Global Peptide-Radionuclide Conjugates (PRCs) Market Product Outlook & Forecast (2021-2033) Value (USD Million)

6.1.1. Global Peptide-Radionuclide Conjugates (PRCs) Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.2. Global Peptide-Radionuclide Conjugates (PRCs) Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.1.3. Global Peptide-Radionuclide Conjugates (PRCs) Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

6.2. Global Peptide-Radionuclide Conjugates (PRCs) Market Product Outlook & Forecast (2021-2033) Volume (K)

6.2.1. Global Peptide-Radionuclide Conjugates (PRCs) Market Volume (K) and CAGR (%) by Application (2020-2032)

6.2.2. Global Peptide-Radionuclide Conjugates (PRCs) Market Volume (K) and CAGR (%) by Types (2020-2032)

6.2.3. Global Peptide-Radionuclide Conjugates (PRCs) Market Volume (K) and CAGR (%) by Region (2020-2032)

7. Global Peptide-Radionuclide Conjugates (PRCs) Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Peptide-Radionuclide Conjugates (PRCs) Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Peptide-Radionuclide Conjugates (PRCs) Market Breakdown Data By Volume (K) (2020-2032)

8.1. Global Peptide-Radionuclide Conjugates (PRCs) Market by: Regions (Volume)

8.1.1. North America

8.1.2. South America

8.1.3. Europe

8.1.4. Middle East & Africa

8.1.5. Asia Pacific

8.2. North America

8.2.1. North America Volume (K) (2020-2032) By Country

8.2.2. North America Volume (K) (2020-2032) by Application

8.2.3. North America Volume (K) (2020-2032) by Types

8.3. South America

8.3.1. South America Volume (K) (2020-2032) By Country

8.3.2. South America Volume (K) (2020-2032) by Application

8.3.3. South America Volume (K) (2020-2032) by Types

8.4. Europe

8.4.1. Europe Volume (K) (2020-2032) By Country

8.4.2. Europe Volume (K) (2020-2032) by Application

8.4.3. Europe Volume (K) (2020-2032) by Types

8.5. Middle East & Africa

8.5.1. Middle East & Africa Volume (K) (2020-2032) By Country

8.5.2. Middle East & Africa Volume (K) (2020-2032) by Application

8.5.3. Middle East & Africa Volume (K) (2020-2032) by Types

8.6. Asia Pacific

8.6.1. Asia Pacific Volume (K) (2020-2032) By Country

8.6.2. Asia Pacific Volume (K) (2020-2032) by Application

8.6.3. Asia Pacific Volume (K) (2020-2032) by Types

9. Global Peptide-Radionuclide Conjugates (PRCs) Market Competition by Key Manufacturers

9.1. Global Peptide-Radionuclide Conjugates (PRCs) Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

9.2. Player's Concentration

9.2.1. Top 5 Manufacturers

9.2.2. Top 3 Manufacturers

9.3. Market Entropy

Global Peptide-Radionuclide Conjugates (PRCs): Profiled Players Head Office and Area Served

9.4. Key Player Products/Services

9.4.1 Merger & Acquisitions and Expansion Plans

10. Company Profile

10.1. Novartis

10.1.1. Company Basic Information and Sales Area

10.1.2. Main Business/Business Overview

10.1.3. Product Portfolio

10.1.4. Financial

10.1.5. Recent Industry Insights

10.1.6. SWOT Analysis

10.2. RadioMedix

10.2.1. Company Basic Information and Sales Area

10.2.2. Main Business/Business Overview

10.2.3. Product Portfolio

10.2.4. Financial

10.2.5. Recent Industry Insights

10.2.6. SWOT Analysis

10.3. Curium Pharma

10.3.1. Company Basic Information and Sales Area

10.3.2. Main Business/Business Overview

10.3.3. Product Portfolio

10.3.4. Financial

10.3.5. Recent Industry Insights

10.3.6. SWOT Analysis

10.4. Telix Pharmaceutical

10.4.1. Company Basic Information and Sales Area

10.4.2. Main Business/Business Overview

10.4.3. Product Portfolio

10.4.4. Financial

10.4.5. Recent Industry Insights

10.4.6. SWOT Analysis

10.5. ITM Radiopharma

10.5.1. Company Basic Information and Sales Area

10.5.2. Main Business/Business Overview

10.5.3. Product Portfolio

10.5.4. Financial

10.5.5. Recent Industry Insights

10.5.6. SWOT Analysis

10.6. Grand Pharmaceutical

10.6.1. Company Basic Information and Sales Area

10.6.2. Main Business/Business Overview

10.6.3. Product Portfolio

10.6.4. Financial

10.6.5. Recent Industry Insights

10.6.6. SWOT Analysis

11. Methodology/Research Approach

11.1. Research Programs/Material Type

11.2. Market Size Estimation

11.3. Market Breakdown and Data Triangulation

12. Data Sources

12.1. Secondary Sources

12.2. Primary Sources

List of Figures

40 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Peptide-Radionuclide Conjugates (PRCs) Market

Figure 4: Global Peptide-Radionuclide Conjugates (PRCs) Market: Drivers

Figure 5: Global Peptide-Radionuclide Conjugates (PRCs) Market: Challenges

Figure 6: Global Peptide-Radionuclide Conjugates (PRCs) Market: Trends

Figure 7: Global Peptide-Radionuclide Conjugates (PRCs) Market: Opportunity

Figure 8: Global Peptide-Radionuclide Conjugates (PRCs) Market: Restraint

Figure 9: Global Peptide-Radionuclide Conjugates (PRCs) Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Market Volume (K) (2020-2024) By Application

Figure 15: Global Market Share (%) By Application (2024)

Figure 16: Global Market Volume (K) (2020-2024) By Types

Figure 17: Global Market Share (%) By Types (2024)

Figure 18: Global Peptide-Radionuclide Conjugates (PRCs) Market Value (USD Million) By Region

Figure 19: Global Peptide-Radionuclide Conjugates (PRCs) Market Share (%) By: Regions (2024)

Figure 20: Top 5 Manufacturers

Figure 21: Top 3 Manufacturers

Figure 22: Global Market Value (USD Million) (2025-2032) By Application

Figure 23: Global Market Share (%) By Application (2032)

Figure 24: Global Market Value (USD Million) (2025-2032) By Types

Figure 25: Global Market Share (%) By Types (2032)

Figure 26: Global Peptide-Radionuclide Conjugates (PRCs) Market Value (USD Million) By Region

Figure 27: Global Peptide-Radionuclide Conjugates (PRCs) Market Share (%) By: Regions (2032)

Figure 28: Global Peptide-Radionuclide Conjugates (PRCs) Market Volume (K) By Region

Figure 29: Global Peptide-Radionuclide Conjugates (PRCs) Market Share (%) By: Regions (2024)

Figure 30: Top 5 Manufacturers

Figure 31: Top 3 Manufacturers

Figure 32: Global Market Volume (K) (2025-2032) By Application

Figure 33: Global Market Share (%) By Application (2032)

Figure 34: Global Market Volume (K) (2025-2032) By Types

Figure 35: Global Market Share (%) By Types (2032)

Figure 36: Global Peptide-Radionuclide Conjugates (PRCs) Market Value (USD Million) By Region

Figure 37: Global Peptide-Radionuclide Conjugates (PRCs) Market Share (%) By: Regions (2032)

Figure 38: Global Peptide-Radionuclide Conjugates (PRCs) Market Volume (K) By Region

Figure 39: Global Peptide-Radionuclide Conjugates (PRCs) Market Share (%) By: Regions (2032)

Figure 40: Data Triangulation

List of Tables

107 items

Table 1: Market Segmentation Analysis

Table 2: Global Peptide-Radionuclide Conjugates (PRCs) Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Peptide-Radionuclide Conjugates (PRCs) Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Peptide-Radionuclide Conjugates (PRCs) Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Market Volume (K) (2020-2024) By Application

Table 10: Global Market Share (%) By Application (2024)

Table 11: Global Market Volume (K) (2020-2024) By Types

Table 12: Global Market Share (%) By Types (2024)

Table 13: Global Peptide-Radionuclide Conjugates (PRCs) Market Value (USD Million) By Region

Table 14: Global Peptide-Radionuclide Conjugates (PRCs) Market Share (%) By Region

Table 15: North America Market Value (USD Million) (2020-2024) By Country

Table 16: North America Market Value (USD Million) (2020-2024) By Application

Table 17: North America Market Value (USD Million) (2020-2024) By Types

Table 18: Europe Market Value (USD Million) (2020-2024) By Country

Table 19: Europe Market Value (USD Million) (2020-2024) By Application

Table 20: Europe Market Value (USD Million) (2020-2024) By Types

Table 21: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 22: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 23: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 24: South America Market Value (USD Million) (2020-2024) By Country

Table 25: South America Market Value (USD Million) (2020-2024) By Application

Table 26: South America Market Value (USD Million) (2020-2024) By Types

Table 27: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 28: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 29: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 30: Global Peptide-Radionuclide Conjugates (PRCs) Market Volume (K) By Region

Table 31: Global Peptide-Radionuclide Conjugates (PRCs) Market Share (%) By Region

Table 32: North America Market Volume (K) (2020-2024) By Country

Table 33: North America Market Volume (K) (2020-2024) By Application

Table 34: North America Market Volume (K) (2020-2024) By Types

Table 35: Europe Market Volume (K) (2020-2024) By Country

Table 36: Europe Market Volume (K) (2020-2024) By Application

Table 37: Europe Market Volume (K) (2020-2024) By Types

Table 38: Asia Pacific Market Volume (K) (2020-2024) By Country

Table 39: Asia Pacific Market Volume (K) (2020-2024) By Application

Table 40: Asia Pacific Market Volume (K) (2020-2024) By Types

Table 41: South America Market Volume (K) (2020-2024) By Country

Table 42: South America Market Volume (K) (2020-2024) By Application

Table 43: South America Market Volume (K) (2020-2024) By Types

Table 44: Middle East & Africa Market Volume (K) (2020-2024) By Country

Table 45: Middle East & Africa Market Volume (K) (2020-2024) By Application

Table 46: Middle East & Africa Market Volume (K) (2020-2024) By Types

Table 47: Global Peptide-Radionuclide Conjugates (PRCs) Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 48: Global Peptide-Radionuclide Conjugates (PRCs) Market: Profiled Players Head Office And Area Served

Table 49: Key Players Global Peptide-Radionuclide Conjugates (PRCs) Market:

Table 50: Mergers & Acquisitions, Expansion Plans

Table 51: Novartis Basic Information And Sales Area

Table 52: Novartis. Products Portfolio

Table 53: RadioMedix Basic Information And Sales Area

Table 54: RadioMedix. Products Portfolio

Table 55: Curium Pharma Basic Information And Sales Area

Table 56: Curium Pharma. Products Portfolio

Table 57: Telix Pharmaceutical Basic Information And Sales Area

Table 58: Telix Pharmaceutical. Products Portfolio

Table 59: ITM Radiopharma Basic Information And Sales Area

Table 60: ITM Radiopharma. Products Portfolio

Table 61: Grand Pharmaceutical Basic Information And Sales Area

Table 62: Grand Pharmaceutical. Products Portfolio

Table 63: Global Market Value (USD Million) (2025-2032) By Application

Table 64: Global Market Share (%) By Application (2032)

Table 65: Global Market Value (USD Million) (2025-2032) By Types

Table 66: Global Market Share (%) By Types (2032)

Table 67: Global Market Volume (K) (2025-2032) By Application

Table 68: Global Market Share (%) By Application (2032)

Table 69: Global Market Volume (K) (2025-2032) By Types

Table 70: Global Market Share (%) By Types (2032)

Table 71: Global Peptide-Radionuclide Conjugates (PRCs) Market Value (USD Million) By Region

Table 72: Global Peptide-Radionuclide Conjugates (PRCs) Market Share (%) By Region (2025-2032)

Table 73: North America Market Value (USD Million) (2025-2032) By Country

Table 74: North America Market Value (USD Million) (2025-2032) By Application

Table 75: North America Market Value (USD Million) (2025-2032) By Types

Table 76: Europe Market Value (USD Million) (2025-2032) By Country

Table 77: Europe Market Value (USD Million) (2025-2032) By Application

Table 78: Europe Market Value (USD Million) (2025-2032) By Types

Table 79: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 80: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 81: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 82: South America Market Value (USD Million) (2025-2032) By Country

Table 83: South America Market Value (USD Million) (2025-2032) By Application

Table 84: South America Market Value (USD Million) (2025-2032) By Types

Table 85: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 86: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 87: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 88: Global Peptide-Radionuclide Conjugates (PRCs) Market Volume (K) By Region

Table 89: Global Peptide-Radionuclide Conjugates (PRCs) Market Share (%) By Region (2025-2032)

Table 90: North America Market Volume (K) (2025-2032) By Country

Table 91: North America Market Volume (K) (2025-2032) By Application

Table 92: North America Market Volume (K) (2025-2032) By Types

Table 93: Europe Market Volume (K) (2025-2032) By Country

Table 94: Europe Market Volume (K) (2025-2032) By Application

Table 95: Europe Market Volume (K) (2025-2032) By Types

Table 96: Asia Pacific Market Volume (K) (2025-2032) By Country

Table 97: Asia Pacific Market Volume (K) (2025-2032) By Application

Table 98: Asia Pacific Market Volume (K) (2025-2032) By Types

Table 99: South America Market Volume (K) (2025-2032) By Country

Table 100: South America Market Volume (K) (2025-2032) By Application

Table 101: South America Market Volume (K) (2025-2032) By Types

Table 102: Middle East & Africa Market Volume (K) (2025-2032) By Country

Table 103: Middle East & Africa Market Volume (K) (2025-2032) By Application

Table 104: Middle East & Africa Market Volume (K) (2025-2032) By Types

Table 105: Research Programs/Design For This Report

Table 106: Key Data Information From Secondary Sources

Table 107: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

Peptide-Radionuclide Conjugates (PRCs) Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	1.20 billion
Revenue forecast in 2033	3.15 billion
Growth rate	CAGR of 12.8% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Novartis; RadioMedix; Curium Pharma; Telix Pharmaceutical; ITM Radiopharma; Grand Pharmaceutical
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

Restraints2 items

Opportunities2 items

Challenges2 items

Market Segmentation

Loading chart…

Peptide-Radionuclide Conjugates (PRCs) Segmentation Breakdown7 items

Application

Prostate Cancer

Neuroendocrine Tumors

Other

Types

Diagnostic PRCs

Therapeutic PRCs

Regional Insights

Loading chart…

Competitive Landscape

Novartis: regional expansion

RadioMedix: innovation pipeline

Curium Pharma: vertical integration

Telix Pharmaceutical: premium pricing

ITM Radiopharma: local manufacturing

Grand Pharmaceutical: OEM tie-ups

Key Peptide-Radionuclide Conjugates (PRCs) Companies6 items

Novartis

RadioMedix

Curium Pharma

Telix Pharmaceutical

ITM Radiopharma

Grand Pharmaceutical

Market Ecosystem

Raw material/component suppliers — provide critical components

Technology providers — develop PRCs technologies

OEMs / manufacturers — produce PRCs products

System integrators / EPCs — integrate PRCs into treatment protocols

Distributors / channel partners — deliver PRCs to healthcare facilities

Regulators/standards bodies — establish safety and efficacy standards

End users / buyers — administer PRCs to patients

Recent Industry Insights

Analyst Overview

Table of Contents